Omnia SanaPlant Comparison
Goldenrod vs Common coltsfoot
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Goldenrod and Common coltsfoot: both belong to the Asteraceae family; they share 3 indicated uses (arthritis / joint pain, inflammation (general), skin irritation); 1 pharmacological action in common.
Evidence face-off — shared uses
| Condition | Goldenrod | Common coltsfoot | Verdict |
|---|---|---|---|
| Arthritis / joint pain | 1/10 | 1/10 | Comparable evidence |
| Inflammation (general) | 2/10 | 2/10 | Comparable evidence |
| Skin irritation | 1/10 | 1/10 | Comparable evidence |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
Hepatotoxic constituents that are the central safety concern for this plant; regulatory limits and PA-controlled/PA-reduced products exist specifically because of these compounds.
Demulcent polysaccharide contributing to the traditional soothing action on irritated airways.
Pharmacological Actions
Traditional & Indicated Uses
inferred from anti-inflammatory action
inferred from anticancer action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from diuretic action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from sedative action
Safety, Cautions & Contraindications
Generally well tolerated. Not recommended in cases of fluid retention due to impaired cardiac or renal function. Ensure adequate fluid intake when using as a diuretic. May cause allergic reactions in individuals sensitive to Asteraceae plants. Avoid use during pregnancy and breastfeeding due to limited safety data.
Duke (2002) provides clinical evidence (score 2) for goldenrod's anti-inflammatory activity, consistent with Commission E approval. It is also classified as an aquaretic (increases urine output without electrolyte loss) and antispasmodic, used for urinary tract irrigation therapy. Dose: 6–12 g dried herb daily as tea for urinary complaints. Duke cautions against use in cases of edema from renal or cardiac insufficiency, and notes that the herb may cause allergic reactions in individuals sensitive to Asteraceae plants (Duke, 2002).
Safety notes (contraindications, interactions, pregnancy/lactation notes, adverse effects, dose-duration cautions) Important: Coltsfoot naturally contains pyrrolizidine alkaloids (PAs)—plant chemicals that can damage the liver and may increase cancer risk with enough exposure (EMA, 2021; Kopp et al., 2020).
Because of this, European regulators set very strict limits for PA exposure from herbal products (EMA, 2021).
Many safety-focused herbal references recommend avoiding homemade/internal coltsfoot use, unless the product is specifically made to be PA-controlled / PA-reduced (EMA, 2021).
Avoid internal use if you are pregnant or breastfeeding, have liver disease, or for children—these groups are treated as “sensitive” in PA risk guidance (EMA, 2021).
Medication caution: if you take medicines that stress the liver (some prescription drugs can), it’s extra important to avoid unregulated PA exposure (general PA risk logic; consult a clinician) (EMA, 2021).
Topical use may still carry PA considerations; EMA discusses limits and recommends use only on intact skin for PA-containing products (EMA, 2021).
Duke (2002) provides clinical support (score 2) for coltsfoot's anti-inflammatory and expectorant effects, explaining its traditional use in bronchitis and coughs. However, the plant contains hepatotoxic pyrrolizidine alkaloids (PAs), and Duke notes a carcinogenic score (1) — a critical safety concern. Commission E has placed restrictions on coltsfoot use, recommending maximum internal use of 4–6 weeks per year and avoiding use in pregnancy, lactation, and in children under 12. Duke rates its overall safety as low (+) and emphasizes that preparations free of PAs are preferred (Duke, 2002).
External Ids
Botanical Description
Perennial herb (Asteraceae), 20-100 cm tall, with erect, often reddish, downy or smooth stems. Leaves are alternate, lance-shaped and toothed. Numerous small, bright yellow, daisy-like flower heads are clustered into branched, plume-like terminal sprays, followed by small ribbed achenes with a tuft of hairs (pappus).[1]
Low perennial herb notable for flowering before its leaves appear: solitary, bright yellow, dandelion-like flower heads emerge on scaly pinkish stalks in very early spring, followed later by large, hoof-shaped (heart-shaped with angular teeth), white-woolly-backed leaves arising directly from the creeping rhizome.[11]
Habitat
Grows on disturbed, damp or clay-rich waste ground, riverbanks, railway embankments and bare soil; native to Europe, North Africa and temperate Asia and naturalised in North America.[11]
Harvesting
The flowering aerial parts are cut during flowering (late summer) and dried.[11]
Flowers are gathered in very early spring before the leaves appear; leaves are gathered later in the season once expanded. Given the plant's pyrrolizidine alkaloid content, harvesting from a positively confirmed patch (not a look-alike) and preferring PA-tested commercial material for internal use is strongly advised.[2]
Traditional Uses
Goldenrod has a long European folk-medicine tradition as a mild 'aquaretic' diuretic and anti-inflammatory remedy for the urinary tract, used traditionally for urinary-tract irrigation therapy alongside adequate fluid intake, and topically as a wound herb (one common name is 'woundwort'). Modern phytochemical work confirms saponin- and flavonoid-driven anti-inflammatory, antioxidant and diuretic activity.[1, 11]
Coltsfoot has an ancient European and Chinese tradition, reflected in its Latin name (tussis = cough), as an expectorant and demulcent remedy for coughs, bronchitis and irritated airways; because of its pyrrolizidine alkaloid content, contemporary use is restricted to short courses of PA-controlled preparations under regulatory limits (see contraindications).[1, 2, 12]
Preparations
Dried aerial parts steeped in hot water - the classic urinary-tract preparation.
Commercially prepared, pyrrolizidine-alkaloid-tested extract or syrup, the only form recommended for internal use given the plant's natural PA content.
Dried flower or leaf infused in hot water; traditional but subject to strict duration/PA-content limits under EU herbal regulation.
Dosage
EU regulatory guidance restricts internal use to PA-controlled preparations. The EMA public statement on unsaturated pyrrolizidine alkaloids records a maximum daily intake for internal use of 1 microgram of PAs for at most 6 weeks per year, or 0.1 microgram per day with no duration limit; for cutaneous use the limits are 100 micrograms for at most 6 weeks per year, or 10 micrograms without a duration limit. Not for use in pregnancy, breastfeeding, or children. Note that these are limits on PA intake, not a herb dose — no EMA monograph exists for Tussilago farfara, so there is no official posology for the herb itself. Educational reference only, not a prescription — consult a qualified practitioner and prefer tested commercial products.
References
Lookalikes Review
Dangerous Lookalikes
References & Sources
- Fursenco, C., Calalb, T., Uncu, L., Dinu, M. and others (2020) 'Solidago virgaurea L.: A Review of Its Ethnomedicinal Uses, Phytochemistry, and Pharmacological Activities', Biomolecules, 10(12), pp. 1619. doi:10.3390/biom10121619 Meta-analysis / review
https://doi.org/10.3390/biom10121619 - Abdel Motaal, A., Ezzat, S.M., Tadros, M.G. and El-Askary, H.I (2016) 'In vivo anti-inflammatory activity of caffeoylquinic acid derivatives from Solidago virgaurea in rats', Pharmaceutical Biology, 54(12), pp. 2864-2870. doi:10.1080/13880209.2016.1190381 Preclinical
https://doi.org/10.1080/13880209.2016.1190381 - Précheur, I., Rolland, Y., Hasseine, L., Orange, F. and others (2020) 'Solidago virgaurea L. Plant Extract Targeted Against Candida albicans to Reduce Oral Microbial Biomass: A Double Blind Randomized Trial on Healthy Adults', Antibiotics, 9(4), pp. 137. doi:10.3390/antibiotics9040137 Randomized trial
https://doi.org/10.3390/antibiotics9040137 - Wojnicz, D., Tichaczek-Goska, D., Glensk, M. and Hendrich, A.B (2021) 'Is It Worth Combining Solidago virgaurea Extract and Antibiotics against Uropathogenic Escherichia coli Rods? An In Vitro Model Study', Pharmaceutics, 13(4), pp. 573. doi:10.3390/pharmaceutics13040573 Preclinical
https://doi.org/10.3390/pharmaceutics13040573 - El-Tantawy, W.H (2013) 'Biochemical effects of Solidago virgaurea extract on experimental cardiotoxicity', Journal of Physiology and Biochemistry, 70(1), pp. 33-42. doi:10.1007/s13105-013-0277-0 Preclinical
https://doi.org/10.1007/s13105-013-0277-0 - Gross, S.C., Goodarzi, G., Watabe, M., Bandyopadhyay, S. and others (2002) 'Antineoplastic activity of Solidago virgaurea on prostatic tumor cells in an SCID mouse model', Nutrition and Cancer, 43(1), pp. 76-81. doi:10.1207/S15327914NC431_9 Preclinical
https://doi.org/10.1207/S15327914NC431_9 - Starks, C.M., Williams, R.B., Goering, M.G., O'Neil-Johnson, M. and others (2010) 'Antibacterial clerodane diterpenes from Goldenrod (Solidago virgaurea)', Phytochemistry, 71(1), pp. 104-109. doi:10.1016/j.phytochem.2009.09.032 Preclinical
https://doi.org/10.1016/j.phytochem.2009.09.032 - Malicanin, M., Karabegovic, I., Dordevic, N., Mancic, S. and others (2024) 'Influence of the Extraction Method on the Biological Potential of Solidago virgaurea L. Essential Oil and Hydrolates', Plants, 13(16), pp. 2187. doi:10.3390/plants13162187 Preclinical
https://doi.org/10.3390/plants13162187 - Zehra, S.A., Bhattarai, P., Zhang, J., Liu, Y. and others (2022) 'Phytochemical Analysis and Evaluation of the Antidiabetic Activity of Solidago virgaurea Extracts', Current Bioactive Compounds, 19(4), pp. e150622206146. doi:10.2174/1573407218666220615143502 Preclinical
https://doi.org/10.2174/1573407218666220615143502 - Jang, Y.S., Wang, Z., Lee, J.M., Lee, J.Y. and others (2016) 'Screening of Korean Natural Products for Anti-Adipogenesis Properties and Isolation of Kaempferol-3-O-rutinoside as a Potent Anti-Adipogenetic Compound from Solidago virgaurea', Molecules, 21(2), pp. 226. doi:10.3390/molecules21020226 Preclinical
https://doi.org/10.3390/molecules21020226 - European Medicines Agency (2008) 'Community herbal monograph on Solidago virgaurea L., herba'. Traditional / reference
https://scholar.google.com/scholar?q=Community%20herbal%20monograph%20on%20Solidago%20virgaurea%20L.%2C%20herba - Bader, G., Binder, K., Hiller, K. and Zwintscher, U (1990) 'The saponins from Solidago virgaurea L', 45(8), pp. 618--622. Traditional / reference
https://scholar.google.com/scholar?q=The%20saponins%20from%20Solidago%20virgaurea%20L - Royal Botanic Gardens, Kew (n.d.). Available at: https://powo.science.kew.org Traditional / reference
https://powo.science.kew.org - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Grow Forage Cook Ferment 'Foraging Goldenrod (Solidago): Identification and Uses'. Available at: https://www.growforagecookferment.com/foraging-goldenrod/ Traditional / reference
https://www.growforagecookferment.com/foraging-goldenrod/ - Washington State Noxious Weed Control Board 'Tansy Ragwort (Senecio jacobaea)'. Available at: https://www.nwcb.wa.gov/weeds/tansy-ragwort Traditional / reference
https://www.nwcb.wa.gov/weeds/tansy-ragwort - Schneider, J. and Tsegaye, Y. and W/Tensae, M. and G/Selassie, S. and Haile, T. and Bane, A. and Ali, A. and Mesfin, G. and Seboxa, T (2012) 'Veno-occlusive liver disease: a case report', Ethiopian Medical Journal, 50 Suppl 2, pp. 47-51. Available at: https://pubmed.ncbi.nlm.nih.gov/22946295/ Clinical study
https://pubmed.ncbi.nlm.nih.gov/22946295/
- Ahmad, I., Kudaibergenova, B., Ahmad, M. and others (2025) 'Coltsfoot (Tussilago farfara L.; Asteraceae): modern methods of extraction, phytochemistry, nanoparticles synthesis, ethnopharmacology, and biological activities', Natural Product Research, pp. 1-20. doi:10.1080/14786419.2025.2548616 Traditional / reference
https://doi.org/10.1080/14786419.2025.2548616 - Chen, S., Dong, L., Quan, H., Zhou, X. and others (2020) 'A review of the ethnobotanical value, phytochemistry, pharmacology, toxicity and quality control of Tussilago farfara L. (coltsfoot)', Journal of Ethnopharmacology, 267, pp. 113478. doi:10.1016/j.jep.2020.113478 Traditional / reference
https://doi.org/10.1016/j.jep.2020.113478 - Feng, J., Zhang, Y., Qin, X., Gao, T. and others (2022) 'Novel Quinic Acid Glycerates from Tussilago farfara Inhibit Polypeptide GalNAc-Transferase', ChemBioChem, 23(3), pp. e202100539. doi:10.1002/cbic.202100539 Preclinical
https://doi.org/10.1002/cbic.202100539 - Zhao, J., Evangelopoulos, D., Bhakta, S., Gray, A.I. and Seidel, V (2014) 'Antitubercular activity of Arctium lappa and Tussilago farfara extracts and constituents', Journal of Ethnopharmacology, 155(1), pp. 796-800. doi:10.1016/j.jep.2014.06.034 Preclinical
https://doi.org/10.1016/j.jep.2014.06.034 - Avila, C., Breakspear, I., Hawrelak, J., Salmond, S. and Evans, S (2020) 'A systematic review and quality assessment of case reports of adverse events for borage (Borago officinalis), coltsfoot (Tussilago farfara) and comfrey (Symphytum officinale)', Fitoterapia, 142, pp. 104519. doi:10.1016/j.fitote.2020.104519 Meta-analysis / review
https://doi.org/10.1016/j.fitote.2020.104519 - Lee, J., Park, S., Kim, M.J., Kwon, S.J. and others (2019) 'Sesquiterpenoids from Tussilago farfara Flower Bud Extract for the Eco-Friendly Synthesis of Silver and Gold Nanoparticles Possessing Antibacterial and Anticancer Activities', Nanomaterials (Basel), 9(6), pp. 819. doi:10.3390/nano9060819 Preclinical
https://doi.org/10.3390/nano9060819 - Bota, V.B., Neamtu, A.A., Olah, N.K., Chiselita, O. and others (2022) 'A Comparative Analysis of the Anatomy, Phenolic Profile, and Antioxidant Capacity of Tussilago farfara L. Vegetative Organs', Plants (Basel), 11(13), pp. 1663. doi:10.3390/plants11131663 Preclinical
https://doi.org/10.3390/plants11131663 - Boucher, M.A., Cote, H., Pichette, A., Ripoll, L. and Legault, J (2020) 'Chemical composition and antibacterial activity of Tussilago farfara (L.) essential oil from Quebec, Canada', Natural Product Research, 34(4), pp. 545-548. doi:10.1080/14786419.2018.1489384 Preclinical
https://doi.org/10.1080/14786419.2018.1489384 - Li, Z.Y., Zhang, J., Zhang, Y.B., Yang, X.W. and others (2022) 'Polyhydroxylated eudesmane sesquiterpenoids and sesquiterpenoid glucoside from the flower buds of Tussilago farfara', Chinese Journal of Natural Medicines, 20(4), pp. 301-308. doi:10.1016/S1875-5364(21)60120-6 Preclinical
https://doi.org/10.1016/S1875-5364(21)60120-6 - Jang, H., Lee, J.W., Lee, C., Jin, Q. and others (2016) 'Sesquiterpenoids from Tussilago farfara inhibit LPS-induced nitric oxide production in macrophage RAW 264.7 cells', Archives of Pharmacal Research, 39(1), pp. 127-132. doi:10.1007/s12272-015-0667-7 Preclinical
https://doi.org/10.1007/s12272-015-0667-7 - Royal Botanic Gardens, Kew (n.d.). Available at: https://powo.science.kew.org Traditional / reference
https://powo.science.kew.org - Westendorf, J., Czok, G., Marquardt, R., Nausner, M., Krauer, B. and Paul, H.L (1988) 'Pyrrolizidine alkaloid content of Tussilago farfara plants from different regions and preparations', pp. 903--909. Traditional / reference
https://scholar.google.com/scholar?q=Pyrrolizidine%20alkaloid%20content%20of%20Tussilago%20farfara%20plants%20from%20different%20regions%20and%20preparations - European Medicines Agency (HMPC) (2021) 'Public statement on the use of herbal medicinal products containing toxic, unsaturated pyrrolizidine alkaloids (PAs), including recommendations regarding contamination of herbal medicinal products with PAs, Revision 1'. Available at: https://www.ema.europa.eu/en/documents/public-statement/public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids-pas-including-recommendations-regarding-contamination-herbal-medicinal-products-pyrrolizidine_en.pdf Traditional / reference
https://www.ema.europa.eu/en/documents/public-statement/public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids-pas-including-recommendations-regarding-contamination-herbal-medicinal-products-pyrrolizidine_en.pdf - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Sperl, W. and Stuppner, H. and Gassner, I. and Judmaier, W. and Dietze, O. and Vogel, W (1995) 'Reversible hepatic veno-occlusive disease in an infant after consumption of pyrrolizidine-containing herbal tea', European Journal of Pediatrics, 154(2), pp. 112-6. doi:10.1007/BF01991912 Clinical study
https://doi.org/10.1007/BF01991912
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.